Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Equivalents (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Cash & Equivalents for 7 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 2.82% year-over-year to $10.7 million, compared with a TTM value of $10.7 million through Dec 2025, down 2.82%, and an annual FY2025 reading of $10.7 million, down 2.82% over the prior year.
  • Cash & Equivalents was $10.7 million for Q4 2025 at aTYR PHARMA, up from $6.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $59.7 million in Q3 2021 and bottomed at $2.2 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $13.4 million, with a median of $10.6 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents plummeted 89.87% in 2021, then soared 327.27% in 2022.
  • Year by year, Cash & Equivalents stood at $2.3 million in 2021, then soared by 327.27% to $10.0 million in 2022, then skyrocketed by 125.87% to $22.5 million in 2023, then plummeted by 50.96% to $11.1 million in 2024, then decreased by 2.82% to $10.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ATYR at $10.7 million in Q4 2025, $6.1 million in Q3 2025, and $17.2 million in Q2 2025.